Here are six updates on gastroenterology and endoscopy companies.
Dublin, Ireland-based Allergan entered a research, development, collaboration and license agreement to develop Indianapolis's Assembly Biosciences microbiome gastrointestinal development programs.
To combat its $30 billion debt, Lovell, Canada-based Valeant Pharmaceuticals is selling its Dendreon cancer business and three of its skincare brands for $2.12 billion.
Valeant Pharmaceuticals' board of directors elected Richard DeSchutter director.
Madison, Wis.-based Exact Sciences — the makers of Cologuard — anticipates revenue between $34.9 and $25.4 million for the fourth quarter of fiscal year 2016.
Blue Cross Blue Shield Association's Center for Clinical Effectiveness positively reviewed Madison, Wis.-based Exact Sciences' Cologuard, a fecal-based colonoscopy alternative.
Japan's Takeda Pharmaceuticals and San Diego's PvP Biologics are developing KumaMax, a novel enzyme that breaks down immune-reactive parts of gluten in the stomach, for patients with Celiac disease.